Jeon D. Infection source and epidemiology of Nontuberculous Mycobacterial Lung Disease. Tuberc Respir Dis. 2018;81.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
Dahl VN, Mølhave M, Fløe A, van Ingen J, Schön T, Lillebaek T, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022;125:120–31.
Kim JY, Kwak N, Yim JJ. The rise in prevalence and related costs of Nontuberculous Mycobacterial diseases in South Korea, 2010–2021. Open Forum Infect Dis. 2022;9(12):ofac649.
Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13.
Prevots DR, Marshall JE, Wagner D, Morimoto K. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: a review. Clin Chest Med. 2023;44(4):675–721.
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr., Andrejak C et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1).
Kwon YS, Koh WJ, Daley CL. Treatment of Mycobacterium avium Complex Pulmonary Disease. Tuberc Respir Dis (Seoul). 2019;82(1):15–26.
Kwon YS, Koh WJ. Diagnosis and treatment of Nontuberculous Mycobacterial Lung Disease. J Korean Med Sci. 2016;31(5):649–59.
Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of Mycobacterium avium Complex Lung Disease: a systematic review and Meta-analysis. Clin Infect Dis. 2017;65(7):1077–84.
Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D et al. Systematic review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus outcomes and Disease Recurrence. Antimicrob Agents Chemother. 2017;61(11).
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin Liposome Inhalation suspension for treatment-refractory lung Disease caused by Mycobacterium avium Complex (CONVERT). A prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198(12):1559–69.
Vinnard C, Mezochow A, Oakland H, Klingsberg R, Hansen-Flaschen J, Hamilton K. Assessing response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis? Front Microbiol. 2018;9:2813.
Yoshizawa K, Aoki A, Shima K, Tanabe Y, Koya T, Hasegawa T et al. Serum anti-interferon-gamma Autoantibody Titer as a potential biomarker of disseminated non-tuberculous mycobacterial infection. J Clin Immunol. 2020.
van Ingen J, Aksamit T, Andrejak C, Bottger EC, Cambau E, Daley CL et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018;51(3).
Dreszer TR, Karolchik D, Zweig AS, Hinrichs AS, Raney BJ, Kuhn RM, et al. The UCSC Genome Browser database: extensions and updates 2011. Nucleic Acids Res. 2012;40(Database issue):D918–23.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–3.
Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29(5):661–3.
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.
Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, et al. Novel blood-based Transcriptional Biomarker panels predict the late-phase Asthmatic Response. Am J Respir Crit Care Med. 2018;197(4):450–62.
Biasci D, Lee JC, Noor NM, Pombal DR, Hou M, Lewis N, et al. A blood-based prognostic biomarker in IBD. Gut. 2019;68(8):1386–95.
Arindrarto W, Borràs DM, de Groen RAL, van den Berg RR, Locher IJ, van Diessen S, et al. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia. 2021;35(1):47–61.
Yoo H, Kim HJ, Yang SH, Son GH, Gim JA, Lee HW, et al. Gene expression profiling of the habenula in rats exposed to Chronic Restraint stress. Mol Cells. 2022;45(5):306–16.
Kim CH, Choi G, Lee J. Host blood transcriptional signatures as candidate biomarkers for Predicting progression to active tuberculosis. Tuberc Respir Dis (Seoul). 2023;86(2):94–101.
Vargas R, Abbott L, Bower D, Frahm N, Shaffer M, Yu WH. Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment. PLoS Comput Biol. 2023;19(7):e1010770.
Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. The Lancet Respiratory Medicine; 2020.
Turner CT, Gupta RK, Tsaliki E, Roe JK, Mondal P, Nyawo GR, et al. Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. The Lancet Respiratory Medicine; 2020.
Sutherland JS, van der Spuy G, Gindeh A, Thuong NTT, Namuganga A, Owolabi O, et al. Diagnostic accuracy of the Cepheid 3-gene host response Fingerstick Blood Test in a Prospective, multi-site study: interim results. Clin Infect Dis. 2022;74(12):2136–41.
Matsuyama M, Martins AJ, Shallom S, Kamenyeva O, Kashyap A, Sampaio EP, et al. Transcriptional response of respiratory epithelium to Nontuberculous Mycobacteria. Am J Respir Cell Mol Biol. 2018;58(2):241–52.
Cowman SA, Jacob J, Hansell DM, Kelleher P, Wilson R, Cookson WOC, et al. Whole-blood gene expression in pulmonary nontuberculous mycobacterial infection. Am J Respir Cell Mol Biol. 2018;58(4):510–8.
Cho J, Park K, Choi SM, Lee J, Lee CH, Lee JK et al. Genome-wide association study of non-tuberculous mycobacterial pulmonary disease. Thorax. 2020.
Ratnatunga CN, Lutzky VP, Kupz A, Doolan DL, Reid DW, Field M, et al. The rise of Non-tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303.
Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet. 2007;16:2:R183–94.
Mira MT, Alcaïs A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004;427(6975):636–40.
Chopra R, Ali S, Srivastava AK, Aggarwal S, Kumar B, Manvati S, et al. Mapping of PARK2 and PACRG overlapping regulatory region reveals LD structure and functional variants in association with leprosy in unrelated Indian population groups. PLoS Genet. 2013;9(7):e1003578.
Capela C, Dossou AD, Silva-Gomes R, Sopoh GE, Makoutode M, Menino JF, et al. Genetic variation in Autophagy-related genes influences the risk and phenotype of Buruli Ulcer. PLoS Negl Trop Dis. 2016;10(4):e0004671.
Ali S, Vollaard AM, Widjaja S, Surjadi C, van de Vosse E, van Dissel JT. PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever. Clin Exp Immunol. 2006;144(3):425–31.
Huang J, Brumell JH. Bacteria-autophagy interplay: a battle for survival. Nat Rev Microbiol. 2014;12(2):101–14.
Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature. 2013;501(7468):512–6.
Matheoud D, Sugiura A, Bellemare-Pelletier A, Laplante A, Rondeau C, Chemali M, et al. Parkinson’s Disease-related proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. 2016;166(2):314–27.
Hong SJ, Jung S, Jang JS, Mo S, Kwon JO, Kim MK, et al. PARK2 induces osteoclastogenesis through activation of the NF-κB pathway. Mol Cells. 2022;45(10):749–60.
de Léséleuc L, Orlova M, Cobat A, Girard M, Huong NT, Ba NN, et al. PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. PLoS Negl Trop Dis. 2013;7(1):e2015.
Huber ME, Kurapova R, Heisler CM, Karamooz E, Tafesse FG, Harriff MJ. Rab6 regulates recycling and retrograde trafficking of MR1 molecules. Sci Rep. 2020;10(1):20778.
Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 inhibition beyond thrombosis: effects on inflammation. Int J Mol Sci. 2020;21(4).
Ronnow SR, Sand JMB, Langholm LL, Manon-Jensen T, Karsdal MA, Tal-Singer R, et al. Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. Respir Res. 2019;20(1):63.
Weckmann M, Bahmer T, Sand JM, Rank Rønnow S, Pech M, Vermeulen C et al. COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. Eur Respir J. 2021;58(6).
Singh B, Fleury C, Jalalvand F, Riesbeck K. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. FEMS Microbiol Rev. 2012;36(6):1122–80.
Hansel NN, Gao L, Rafaels NM, Mathias RA, Neptune ER, Tankersley C, et al. Leptin receptor polymorphisms and lung function decline in COPD. Eur Respir J. 2009;34(1):103–10.
Li Z, Xu D, Jing J, Wang J, Jiang M, Li F. Identification and Validation of Prognostic Markers for Lung Squamous Cell Carcinoma Associated with Chronic Obstructive Pulmonary Disease. J Oncol. 2022;2022:4254195.
Moll M, Boueiz A, Ghosh AJ, Saferali A, Lee S, Xu Z, et al. Development of a blood-based transcriptional risk score for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2022;205(2):161–70.
Add Comment